Department of Atomic Energy launches nutraceutical AKTOCYTE

The AKTOCYTE tablets have shown remarkable results, particularly in pelvic cancer patients suffering from radiotherapy-induced side effects

The Department of Atomic Energy in collaboration with M/s. IDRS Labs Pvt. Ltd. Bengaluru has launched a Food Supplement / Nutraceutical AKTOCYTE which is aimed at enhancing the quality of life for cancer patients undergoing radiotherapy. Scientists from Bhabha Atomic Research Centre, Mumbai; Advanced Centre for Training Research and Education in Cancer, Navi Mumbai, Tata Memorial Hospital, Mumbai; and M/s. IDRS Labs who were involved in the making of the tablets were present during the launch programme.

AKTOCYTE has received approval from the Food Safety and Standards Authority of India (FSSAI). The development of AKTOCYTE tablets is supported by decades of scientific research at DAE. This product will be a landmark contribution towards affordable cancer care in India and the AKTOCYTE tablets will now be available in the market.

The AKTOCYTE tablets have shown remarkable results, particularly in pelvic cancer patients suffering from radiotherapy-induced side effects. Patients treated with AKTOCYTE tablets demonstrated an extraordinary recovery from radiotherapy-mediated toxicity. The tablets, designed as an adjuvant to cancer radiotherapy, regenerative nutraceutical, immunomodulator, and antioxidant, mark a significant advancement in cancer care.

Speaking on the occasion, Vivek Bhasin Director of BARC appreciated the efforts of DAE scientists and M/s. IDRS for the successful commercialisation and stated that tremendous research by all stakeholders has culminated in the launch of the product which will go a long way in preventing radiation damage to healthy tissue during treatment of cancer.